What is the share price of Amerise Biosciences Ltd (AMERISE) today?
The share price of AMERISE as on 20th March 2025 is ₹0.93. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Amerise Biosciences Ltd (AMERISE) share?
The past returns of Amerise Biosciences Ltd (AMERISE) share are- Past 1 week: 4.65%
- Past 1 month: -2.17%
- Past 3 months: -22.50%
- Past 6 months: 10.71%
- Past 1 year: 36.76%
- Past 3 years: -35.86%
- Past 5 years: 13.41%
What are the peers or stocks similar to Amerise Biosciences Ltd (AMERISE)?
The peers or stocks similar to Amerise Biosciences Ltd (AMERISE) include:What is the market cap of Amerise Biosciences Ltd (AMERISE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Amerise Biosciences Ltd (AMERISE) is ₹6.14 Cr as of 20th March 2025.What is the 52 week high and low of Amerise Biosciences Ltd (AMERISE) share?
The 52-week high of Amerise Biosciences Ltd (AMERISE) is ₹1.45 and the 52-week low is ₹0.55.What is the PE and PB ratio of Amerise Biosciences Ltd (AMERISE) stock?
The P/E (price-to-earnings) ratio of Amerise Biosciences Ltd (AMERISE) is -43.89. The P/B (price-to-book) ratio is 1.14.Which sector does Amerise Biosciences Ltd (AMERISE) belong to?
Amerise Biosciences Ltd (AMERISE) belongs to the Materials sector & Wood Products sub-sector.How to buy Amerise Biosciences Ltd (AMERISE) shares?
You can directly buy Amerise Biosciences Ltd (AMERISE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Amerise Biosciences Ltd
AMERISE Share Price
0.933.33% (+0.03)
AMERISE Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
AMERISE Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
AMERISE Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -76.81 | 1.14 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 29.11 | 3.31 | 1.43% |
AMERISE Analyst Ratings & Forecast
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
AMERISE Company Profile
Amerise Biosciences Ltd is currently inactive and did not generate any revenue.
AMERISE Similar Stocks (Peers)
Compare with peersCENTURYPLY
PE Ratio
47.94
1Y Return
11.78%
Buy Reco %
64.71
GREENPLY
PE Ratio
49.88
1Y Return
23.11%
Buy Reco %
100.00
GREENPANEL
PE Ratio
19.84
1Y Return
24.88%
Buy Reco %
40.00
PE Ratio
31.77
1Y Return
173.07%
Buy Reco %
—
PE Ratio
60.26
1Y Return
18.03%
Buy Reco %
—
AMERISE Forecasts
Price
Revenue
Earnings
AMERISE Share Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeAMERISE Company Revenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeAMERISE Stock EPS (Earnings Per Share) Forecast
Hmm, looks like data is unavailable here. Please come back after some timeAMERISE
Income
Balance Sheet
Cash Flow
Annual Normal View
AMERISE Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 1.18 | 0.00 | — | 9.58 | 0.01 | 0.04 | 0.04 | ||||||||||
Raw Materials | — | — | — | — | — | — | — | — | — | 0.12 | ||||||||||
| Power & Fuel Cost | — | — | — | — | — | — | — | — | — | |||||||||||
| Employee Cost | 0.01 | 0.01 | 0.01 | 0.01 | 0.04 | 0.04 | 0.05 | 0.02 | 0.07 | |||||||||||
| Selling & Administrative Expenses | — | — | — | — | — | — | — | — | — | |||||||||||
| Operating & Other expenses | 0.02 | 0.93 | 0.01 | 1.16 | 0.11 | 0.13 | 8.97 | 0.11 | 0.11 | |||||||||||
EBITDA | -0.03 | -0.94 | -0.02 | 0.01 | -0.15 | -0.17 | 0.56 | -0.12 | -0.14 | -0.08 | ||||||||||
| Depreciation/Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| PBIT | -0.03 | -0.94 | -0.02 | 0.01 | -0.15 | -0.17 | 0.56 | -0.12 | -0.14 | -0.08 | ||||||||||
| Interest & Other Items | — | — | — | — | — | — | — | — | — | — | ||||||||||
| PBT | -0.03 | -0.94 | -0.02 | 0.01 | -0.15 | -0.17 | 0.56 | -0.12 | -0.14 | -0.08 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| Net Income | -0.03 | -0.94 | -0.02 | 0.01 | -0.15 | -0.17 | 0.56 | -0.12 | -0.14 | -0.08 | ||||||||||
| EPS | -0.00 | -0.14 | -0.00 | 0.00 | -0.02 | -0.03 | 0.08 | -0.02 | -0.02 | -0.01 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
AMERISE Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFAMERISE Past Performance & Peer Comparison
Comparing 3 stocks from
MaterialsWood Products
Compare valuation on Screener
MaterialsWood Products
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Amerise Biosciences Ltd | -43.89 | 1.14 | — |
| Century Plyboards (India) Ltd | 47.94 | 7.09 | 0.14% |
| Greenply Industries Ltd | 49.88 | 4.92 | 0.18% |
| Greenpanel Industries Ltd | 19.84 | 2.15 | 0.65% |
AMERISE Stock Price Comparison
Compare AMERISE with any stock or ETFCompare AMERISE with any stock or ETF
AMERISE
AMERISE Shareholdings
AMERISE Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
AMERISE Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 1.20%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
AMERISE Shareholding Pattern
AMERISE Shareholding History
Foreign Institutions
smallcases containing AMERISE stock
Looks like this stock is not in any smallcase yet.
AMERISE Events
AMERISE Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
AMERISE has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
AMERISE Dividends
Hmm, looks like data is unavailable here. Please come back after some timeAMERISE Stock News & Opinions
Articles & Videos
Earnings
Amerise Biosciences reports standalone net loss of Rs 0.02 crore in the December 2024 quarter
Net Loss of Amerise Biosciences reported to Rs 0.02 crore in the quarter ended December 2024 as against net loss of Rs 0.06 crore during the previous quarter ended December 2023. There were no Sales reported in the quarter ended December 2024 and during the previous quarter ended December 2023.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Amerise Biosciences schedules board meeting
Amerise Biosciences will hold a meeting of the Board of Directors of the Company on 3 February 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Amerise Biosciences reports standalone net loss of Rs 0.03 crore in the September 2024 quarter
Net Loss of Amerise Biosciences reported to Rs 0.03 crore in the quarter ended September 2024 as against net loss of Rs 0.04 crore during the previous quarter ended September 2023. There were no Sales reported in the quarter ended September 2024 and during the previous quarter ended September 2023.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Amerise Biosciences schedules board meeting
Amerise Biosciences will hold a meeting of the Board of Directors of the Company on 22 October 2024.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Amerise Biosciences schedules AGM
Amerise Biosciences announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Amerise Biosciences reports standalone net loss of Rs 0.05 crore in the June 2024 quarter
Net Loss of Amerise Biosciences reported to Rs 0.05 crore in the quarter ended June 2024 as against net loss of Rs 0.07 crore during the previous quarter ended June 2023. There were no Sales reported in the quarter ended June 2024 and during the previous quarter ended June 2023.Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Amerise Biosciences to table results
Amerise Biosciences will hold a meeting of the Board of Directors of the Company on 6 August 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Amradeep Industries renames as ‘Amerise Biosciences’
3 years agoIndia Infoline
Amradeep Industries reports standalone net profit of Rs 0.30 crore in the June 2021 quarter
3 years agoBusiness Standard
Amradeep Industries reports standalone net loss of Rs 0.30 crore in the March 2021 quarter
3 years agoBusiness Standard
Over the last 5 years, revenue has grown at a yearly rate of -49.18%, vs industry avg of 11.64%
Over the last 5 years, market share decreased from 0.02% to 0%